Drug-Pricing Help Wanted: Wyden, Grassley Seek Public Input On Policy Ideas
This article was originally published in The Pink Sheet Daily
Following their 2015 report on Gilead's pricing methodology for Sovaldi and Harvoni, senators ask for comments on how to measure value and improve price transparency.
You may also be interested in...
Despite headlines about soaring drug costs, Medicare Part D beneficiaries are not seeing much if any increase in their out-of-pocket spending. But that doesn’t necessarily mean that costs of the program are stable – which could open up a new area for policy activity in 2017 and beyond.
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.